Eosinophilic esophagitis with extremely high esophageal eosinophil counts - 09/01/21
Doi : 10.1016/j.jaci.2020.05.045
| This work was supported by the National Institutes of Health (grants R37 AI045898 [to M.E.R.], R01 AI124355 [to M.E.R.], U19 AI070235 [to M.E.R.]); the Campaign Urging Research for Eosinophilic Disease [to M.E.R.]; the Buckeye Foundation [to M.E.R.]; and the Sunshine Charitable Foundation and its supporters Denise A. Bunning and David G. Bunning [to M.E.R.]). |
|
| Disclosure of potential conflict of interest: M.E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Celgene, AstraZeneca, Allakos, Arena Pharmaceuticals, Guidepoint, and Suvretta Capital Management and has an equity interest in the first 4 companies listed, as well as royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate. In addition, M.E. Rothenberg is an inventor of patents owned by Cincinnati Children’s Hospital. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 147 - N° 1
P. 409 - janvier 2021 Retour au numéro
Article précédent
- Polygenic risk score for atopic dermatitis in the Canadian population
- Mathieu Simard, Anne-Marie Madore, Simon Girard, Susan Waserman, Qingling Duan, Padmaja Subbarao, Malcolm R. Sears, Theo J. Moraes, Allan B. Becker, Stuart E. Turvey, Piushkumar J. Mandhane, Charles Morin, Philippe Bégin, Catherine Laprise
- Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis
- Brian Lipworth, Rory Chan, Chris RuiWen Kuo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?